BAA contract - development of susceptibility guidance for daptomycin and enterococcus species using pharmacometric approaches
Active Definitive Contract Awarded Last action
- Contract number
- 75F40126C00025
- Awardee
-
Institute For Clinical Pharmacodynamics, Inc. UEI Z82HHPY83MC7
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $325,000
Award facts
- Opportunity
-
- FY26 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Special Notice · FDABAA2600123 · Posted Nov 21, 2025
- Contract value 100% obligated
- $325,000.00 Current and potential, with all options
- Completion date 24% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Schenectady, NY 12305, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Food and Drug Administration awarded a $325,000 definitive contract to Institute For Clinical Pharmacodynamics, Inc. on August 1, 2026, for development of susceptibility guidance for daptomycin and enterococcus species using pharmacometric approaches under the FY26 FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science.
Place of performance is Schenectady, NY. The contract runs through July 31, 2027, under firm fixed price terms with no set-aside. The originating BAA solicitation, posted November 21, 2025, seeks basic and applied research and development to support regulatory science and innovation across FDA-regulated domains, with three key charge areas: modernizing development and evaluation of FDA-regulated products, strengthening post-market surveillance and labeling, and invigorating public health preparedness and response. The BAA encompasses research priority areas including new approach methodologies, analytical and computational methods, biomarkers, and clinical outcome assessments. The solicitation is classified under NAICS 541714 (Research and Development in Biotechnology) and PSC code AJ11 (General Science and Technology R&D Services). Multiple awards are anticipated under the BAA, which operated under FAR 6.102(d)(2) and 35.016, with a two-stage submission process and Stage One packages due February 24, 2026.
Quick answers
Who was awarded contract 75F40126C00025?
75F40126C00025 was awarded to Institute For Clinical Pharmacodynamics, Inc. by Food and Drug Administration (Department of Health and Human Services) on August 1, 2026.
How much is contract 75F40126C00025 worth?
The government has obligated $325,000 on 75F40126C00025.
Was contract 75F40126C00025 competed?
The extent of competition for 75F40126C00025 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award